FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks

After the FDA found multiple issues at Biocon’s manufacturing facilities in Malaysia and India, the agency has shot down Biocon and Viatris’ biosimilar to Avastin (bevacizumab).